China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost

Jacobio Pharmaceuticals

24/08/2026 13:54

Overview
China drug developer reported half-year revenue of RMB 730.9 mln
Net income attributable for the half-year was RMB 600.6 mln
Company advanced drug pipeline and licensed JAB-23E73 to AstraZeneca

Outlook
Jacobio expects to submit IND applications for tADC and iADC candidates in Q4 2026

Result Drivers
REGULATORY MILESTONES - Market approval for glecirasib and clinical trial progress for sitneprotafib contributed to results
LICENSING INCOME - Upfront payment from AstraZeneca for JAB-23E73 license boosted results
FOREIGN-EXCHANGE LOSSES – Net FX losses widened to RMB32.6 mln from RMB3.3 mln as the U.S. dollar and Hong Kong dollar depreciated against the RMB

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 730.9 mln
 
H1 Net Income Attributable
 
RMB 600.6 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Jacobio Pharmaceuticals Group Co Ltd is HK$9.74, about 88.8% above its August 24 closing price of HK$5.16
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth
Aug 24 - Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisition
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)